Clene Inc. (CLNN) stock
CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.66−0.26 (-6.63%)
Close on Nov 16, 2026Market cap $47.03MP/E –Yield –
Clene total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Clene's total debt was $964.00K at Sep 30, 2026. For fiscal 2025 it was $3.74M, down 18.9% from the year before. The highest annual figure on record is $14.48M in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.74M | -18.9% |
| FY2024 | Dec 31, 2024 | $4.61M | +143.4% |
| FY2023 | Dec 31, 2023 | $1.89M | -80.0% |
| FY2022 | Dec 31, 2022 | $9.48M | -34.5% |
| FY2021 | Dec 31, 2021 | $14.48M | +84.0% |
| FY2020 | Dec 31, 2020 | $7.87M | +1130.2% |
| FY2019 | Dec 31, 2019 | $640.00K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $964.00K | -78.9% |
| Q2 FY2026 | Jun 30, 2026 | $5.37M | +16.3% |
| Q1 FY2026 | Mar 31, 2026 | $4.63M | +138.4% |
| Q4 FY2025 | Dec 31, 2025 | $3.74M | -18.9% |
| Q3 FY2025 | Sep 30, 2025 | $4.57M | +173.8% |
| Q2 FY2025 | Jun 30, 2025 | $4.62M | +164.7% |
| Q1 FY2025 | Mar 31, 2025 | $1.94M | +6.8% |
| Q4 FY2024 | Dec 31, 2024 | $4.61M | +143.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.67M | -75.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.75M | -89.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.82M | -72.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.89M | -80.0% |
| Q3 FY2023 | Sep 30, 2023 | $6.68M | -57.1% |
| Q2 FY2023 | Jun 30, 2023 | $16.02M | +8.9% |
| Q1 FY2023 | Mar 31, 2023 | $6.71M | -53.7% |
| Q4 FY2022 | Dec 31, 2022 | $9.48M | -35.1% |
| Q2 FY2022 | Jun 30, 2022 | $15.55M | +49.8% |
| Q1 FY2022 | Mar 31, 2022 | $14.71M | +697.8% |
| Q4 FY2021 | Dec 31, 2021 | $14.48M | +84.0% |
| Q3 FY2021 | Sep 30, 2021 | $14.61M | +2183.3% |
| Q2 FY2021 | Jun 30, 2021 | $10.38M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.84M | – |
| Q4 FY2020 | Dec 31, 2020 | $7.87M | – |
| Q4 FY2019 | Dec 31, 2019 | $640.00K | – |
See a number that looks wrong?